BIOLOGÍA MOLECULAR Y CELULAR EN HEMOPATÍAS
Charles University in Prague
Praga, República ChecaPublicaciones en colaboración con investigadores/as de Charles University in Prague (10)
2023
-
Identification of novel genetic loci for risk of multiple myeloma by functional annotation
Leukemia
-
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
International Journal of Molecular Sciences, Vol. 24, Núm. 10
2020
-
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
European Journal of Haematology, Vol. 104, Núm. 5, pp. 435-442
-
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study
Blood, Vol. 136, Núm. 18, pp. 2038-2050
-
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial
Blood Advances, Vol. 4, Núm. 23, pp. 6009-6018
2015
-
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up
British Journal of Haematology, Vol. 171, Núm. 3, pp. 344-354
2013
-
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma
Journal of Clinical Oncology, Vol. 31, Núm. 2, pp. 247-255
2012
-
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
Leukemia, Vol. 26, Núm. 9, pp. 1908-1975
-
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols
Leukemia, Vol. 26, Núm. 9, pp. 1986-2010
2010
-
International network of cancer genome projects
Nature, Vol. 464, Núm. 7291, pp. 993-998